- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rigel Pharmaceuticals Inc (RIGL)
The Rigel share price today is 41.660, view NASDAQ RIGL stock exchange data. Track the latest Rigel share price with real-time updates on RIGL stock performance including market cap, day range, 52-week range and dividend yield. Access RIGL charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.900
41.790
52 wk Range
24.950
52.240
RIGL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.90041.790
52 wk Range
24.95052.240
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RIGL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
55.600
Upside
+33.46%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 55.600
(+33.46% Upside)
Rigel Pharmaceuticals Inc SWOT Analysis
Pipeline Promise | Explore Rigel's R289 and fostamatinib candidates, showing potential in MDS and sickle cell disease, driving future growth prospects |
Financial Turnaround | Rigel achieves positive net income, showcasing strong revenue growth and effective expense management in hematology and oncology sectors |
Market Positioning | Delve into Rigel's strategy of leveraging commercial success to fund pipeline development, balancing current products with future innovations |
Analyst Outlook | Price targets range from $15 to $57, reflecting diverse views on Rigel's growth potential in the competitive biotech landscape |
Rigel Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Rigel posted Q2 2026 EPS of $0.88 vs. $0.21 estimate; revenue hit $78.7M, beating forecast by 43% on record TAVALISSE and REZLIDHIA growth.
- TAVALISSE sales rose 18% YoY to $47.4M; REZLIDHIA climbed 27% to $8.9M; company raised FY2026 revenue guidance to $285M-$295M from $280M-$290M.
- Newly acquired breast-cancer drug VEPPANU launched mid-August; management expects it to drive significant growth but excluded it from current guidance.
- Shares gained 7.5% to $40.22 after-hours; company expects full-year profitability while funding R289 clinical trials for myelodysplastic syndrome.
- Cash declined to $95.3M from $155M at year-end 2025 as R&D costs rose; GAVRETO sales dipped modestly, showing uneven portfolio performance.
Last Updated: 05-08-2026, 03:16 am
Read Full TranscriptEarnings
Latest Release
04-08-2026
EPS / Forecast
0.88 / 0.21
Revenue / Forecast
78.7M / 54.94M
Compare RIGL to Peers and Sector
Metrics to compare | RIGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRIGLPeersSector | |
|---|---|---|---|---|
P/E Ratio | 2.4x | 13.1x | −0.4x | |
PEG Ratio | 0.01 | 0.00 | 0.00 | |
Price/Book | 1.8x | 3.7x | 2.6x | |
Price / LTM Sales | 2.8x | 7.1x | 3.1x | |
Upside (Analyst Target) | 36.9% | 90.2% | 48.2% | |
Fair Value Upside | Unlock | 24.1% | 5.8% | Unlock |
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Rigel (RIGL) Share Price Today?
The Rigel share price today is 41.660.
What is the current Rigel (RIGL) share price and day range?
As of 11-08-2026, the Rigel share price is 41.660, with a previous close of 40.170. The share price has ranged from 39.900 to 41.790 today, while the 52-week range spans from 24.950 to 52.240.
What Is the Rigel Market Cap?
As of today, Rigel market cap is 778.200M.
What Is the Rigel (RIGL) Share Price Target?
The average 12-month share price target for Rigel is 55.600, with a high estimate of 83 and a low estimate of 40. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +33.46% Upside potential.
What Is Rigel's Earnings Per Share (TTM)?
The Rigel EPS (TTM) is 16.451.
When Is the Next Rigel Earnings Date?
Rigel will release its next earnings report on 10-11-2026.
From a Technical Analysis Perspective, Is RIGL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Rigel Trade On?
Rigel is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rigel?
The stock symbol for Rigel is "RIGL."
How Many Times Has Rigel Stock Split?
Rigel has split 2 times.
How Many Employees Does Rigel Have?
Rigel has 173 employees.
What Is the RIGL Premarket Price?
RIGL's last pre-market stock price is 41.740. The pre-market share volume is 600.000, and the stock has changed by 1.570, or 3.910%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.